199 related articles for article (PubMed ID: 32445164)
1. Altered clot formation and lysis are associated with increased fibrinolytic activity in ascites in patients with advanced cirrhosis.
Gitto S; Romanelli RG; Cellai AP; Lami D; Vizzutti F; Abbate R; Margheri F; Fibbi G; Del Rosso M; Laffi G
Intern Emerg Med; 2021 Mar; 16(2):339-347. PubMed ID: 32445164
[TBL] [Abstract][Full Text] [Related]
2. Assessment of fibrinolytic activity by measuring the lysis time of a tissue-factor-induced clot: a feasibility evaluation.
Cellai AP; Lami D; Magi A; Liotta AA; Rogolino A; Antonucci E; Bandinelli B; Abbate R; Prisco D
Clin Appl Thromb Hemost; 2010 Jun; 16(3):337-44. PubMed ID: 19117964
[TBL] [Abstract][Full Text] [Related]
3. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
Colucci M; Binetti BM; Branca MG; Clerici C; Morelli A; Semeraro N; Gresele P
Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
[TBL] [Abstract][Full Text] [Related]
4. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation.
Mosnier LO; von dem Borne PA; Meijers JC; Bouma BN
Thromb Haemost; 1998 Nov; 80(5):829-35. PubMed ID: 9843179
[TBL] [Abstract][Full Text] [Related]
5. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis.
Lisman T; Leebeek FW; Mosnier LO; Bouma BN; Meijers JC; Janssen HL; Nieuwenhuis HK; De Groot PG
Gastroenterology; 2001 Jul; 121(1):131-9. PubMed ID: 11438502
[TBL] [Abstract][Full Text] [Related]
6. Hemostatic changes in patients with liver cirrhosis.
Ho CH; Hou MC; Lin HC; Lee FY; Wu JC; Lee SD
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jun; 62(6):376-82. PubMed ID: 10389296
[TBL] [Abstract][Full Text] [Related]
7. Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study.
Szczepaniak P; Zabczyk M; Undas A
PLoS One; 2015; 10(4):e0125069. PubMed ID: 25909989
[TBL] [Abstract][Full Text] [Related]
8. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests.
Rijken DC; Kock EL; Guimarães AH; Talens S; Darwish Murad S; Janssen HL; Leebeek FW
J Thromb Haemost; 2012 Oct; 10(10):2116-22. PubMed ID: 22906184
[TBL] [Abstract][Full Text] [Related]
9. Clot life span model analysis of clot growth and fibrinolysis in normal subjects: role of thrombin activatable fibrinolysis inhibitor.
Nielsen VG
Blood Coagul Fibrinolysis; 2008 Jun; 19(4):283-7. PubMed ID: 18469549
[TBL] [Abstract][Full Text] [Related]
10. Fibrin Network Formation and Lysis in Septic Shock Patients.
Larsen JB; Aggerbeck MA; Larsen KM; Hvas CL; Hvas AM
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502446
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites.
Thaler J; Lisman T; Quehenberger P; Hell L; Schwabl P; Scheiner B; Bucsics T; Nieuwland R; Ay C; Trauner M; Pabinger I; Reiberger T; Mandorfer M
Thromb Haemost; 2022 Mar; 122(3):353-362. PubMed ID: 34020489
[TBL] [Abstract][Full Text] [Related]
12. Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease.
Agarwal S; Joyner KA; Swaim MW
Am J Gastroenterol; 2000 Nov; 95(11):3218-24. PubMed ID: 11095345
[TBL] [Abstract][Full Text] [Related]
13. Cirrhosis patients have a coagulopathy that is associated with decreased clot formation capacity.
Kleinegris MC; Bos MH; Roest M; Henskens Y; Ten Cate-Hoek A; Van Deursen C; Spronk HM; Reitsma PH; De Groot PG; Ten Cate H; Koek G
J Thromb Haemost; 2014 Oct; 12(10):1647-57. PubMed ID: 25142532
[TBL] [Abstract][Full Text] [Related]
14. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
[TBL] [Abstract][Full Text] [Related]
15. MASP-1 of the complement system alters fibrinolytic behaviour of blood clots.
Jenny L; Noser D; Larsen JB; Dobó J; Gál P; Pál G; Schroeder V
Mol Immunol; 2019 Oct; 114():1-9. PubMed ID: 31325724
[TBL] [Abstract][Full Text] [Related]
16. The hyperfibrinolytic state of liver cirrhosis: possible pathogenetic role of ascites.
Toschi V; Rocchini GM; Motta A; Fiorini GF; Cimminiello C; Violi F; Castelli C; Sironi D; Gibelli A
Biomed Pharmacother; 1993; 47(8):345-52. PubMed ID: 8061256
[TBL] [Abstract][Full Text] [Related]
17. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
18. Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women.
Sidelmann JJ; Kluft C; Krug AH; Winkler U; Jespersen J; Gram JB
Thromb Haemost; 2017 Apr; 117(4):700-705. PubMed ID: 28150855
[TBL] [Abstract][Full Text] [Related]
19. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis.
von dem Borne PA; Meijers JC; Bouma BN
Blood; 1995 Oct; 86(8):3035-42. PubMed ID: 7579397
[TBL] [Abstract][Full Text] [Related]
20. No increased systemic fibrinolysis in women with heavy menstrual bleeding.
Wiewel-Verschueren S; Knol HM; Lisman T; Bogchelman DH; Kluin-Nelemans JC; van der Zee AG; Mulder AB; Meijer K
J Thromb Haemost; 2014 Sep; 12(9):1488-93. PubMed ID: 24954113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
